Beckman Coulter Gets Expanded BARDA Agreement for Sepsis Test

Beckman Coulter has expanded its partnership with HHS’ Biomedical Advanced Research and Development Authority (BARDA) to study the use of the company’s sepsis diagnostic in COVID-19 patients.

The FDA cleared the sepsis diagnostic in April 2019 for use with Dascena’s electronic health record algorithm to predict and detect patients with sepsis.

The aim of the new study is to determine whether the test can aid in the detection of sepsis regardless of whether it is bacterial or viral-induced.